INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nevada) on January 8, 2009, reporting events occurring on January 2, 2009. The filing addresses corporate governance and management changes under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the annual compensation for the newly appointed Chief Financial Officer, set at $135,000.
Material Changes
- Executive Appointment: Robert J. Bowdring was promoted to Chief Financial Officer (CFO) and Chief Accounting Officer, effective January 2, 2009.
- Role Transition: Kathleen Karloff, the Company's Chief Executive Officer, relinquished the Chief Accounting Officer role to Mr. Bowdring.
- Reporting Structure: Mr. Bowdring will report directly to Ms. Karloff.
Management Commentary and Background
Mr. Bowdring, 51, had served as Corporate Controller since October 27, 2008. He brings over 25 years of senior financial management experience, including roles as CFO and Controller at public and private firms such as Cyphermint, Inc. and Lifeline Systems Inc. He holds a Bachelor's degree in Accounting from the University of Massachusetts Amherst. His compensation remains unchanged from his previous employment agreement.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (January 2, 2009).
- Verify the reporting line of the new CFO to the CEO.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Check for any subsequent filings regarding the appointment of a permanent successor if the current role is interim.